| Filed On | Filing |
|---|---|
| 21 Oct 2026 |
Form 4: Dawson John Andrew, Director
Granted 22,700 Stock Option (Right to Buy) |
| 21 Oct 2026 |
Form 3: Dawson John Andrew, Director
No securities owned |
| 21 Oct 2026 |
8-K: Other Events
Overview of PDS Biotech Drug Development Programs (Oncology) NASDAQ: PDSB October 2026 Precision Designed Science for Immunotherapy |
| 20 Oct 2026 |
Form 3: Wendel Bruce, Director
No securities owned |
| 20 Oct 2026 |
Form 3: Ramsdell Deborah, Director
No securities owned |
| 20 Oct 2026 |
Form 4: Ramsdell Deborah, Director
Granted 22,700 Stock Option (Right to Buy) |
| 20 Oct 2026 |
Form 4: Wendel Bruce, Director
Granted 22,700 Stock Option (Right to Buy) |
| 20 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Other Events
John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer (mCRC) and PDS0101 to... |
| 14 Oct 2026 | S-3 |
| 06 Oct 2026 |
8-K: Other Events
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases |
| 22 Sep 2026 |
8-K: Other Events
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology |
| 21 Sep 2026 |
Form 3: Soon-shiong Patrick, Director and 1 other
Holds 13,005,334 shares of Common Stock |
| 21 Sep 2026 |
Form 3: Banaag Arnold James, Director
No securities owned |
| 21 Sep 2026 | SCHEDULE 13D |
| 21 Sep 2026 |
8-K: Other Events
Overview of PDS Biotech Drug Development Programs (Oncology) NASDAQ: PDSB September 2026 |
| 18 Sep 2026 |
Form 3: Trochimiuk Janetta, Principal Accounting Officer
Holds 1,124 shares of Common Stock |
| 14 Sep 2026 |
8-K: Termination of a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +2 more
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors |
| 08 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 7, 2026, by and among PDS Biotechnology Corporation, a Delaware corporation (the “Company”), and the individuals and entities listed on Exhibit A attached to ... |
| 04 Sep 2026 | 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation |
| 25 Aug 2026 | 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation |
Loading...
